PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF) has filed an international patent application for the delivery of CNS-active therapeutic agents covering methods and formulations aimed at addressing treatment challenges in neurological diseases and disorders.
The company has developed an approach for delivering central nervous system (CNS)-active drugs, such as dopamine, directly to the brain, along with formulations adapted for this delivery method. A potential application is Parkinson’s disease, a neurodegenerative condition affecting more than 10—12 million individuals worldwide and is recognized as the second most common neurodegenerative disorder after dementia.
In a statement, Stephen Van Deventer, CEO of PreveCeutical, commented, “Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson’s disease and other CNS disorders.”
